Dr Reddys Laboratories Ltd Analyst Rating
based on 39 analysts
30.77%
Buy
33.33%
Hold
35.90%
Sell
Based on 39 analysts offering long term price targets for Dr Reddys Laboratories Ltd. An average target of ₹1342
Source: S&P Global Market Intelligence
Dr Reddys Laboratories Ltd Share analysis
Dr Reddys Laboratories Ltd price forecast by 39 analysts
Downside of
High
₹1655
Target
₹1342.00
Low
₹969
Dr Reddys Laboratories Ltd target price ₹1342, a slight downside of -0.12% compared to current price of ₹1341.35. According to 39 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Dr Reddys Laboratories Ltd revenue growth forecast
Expected growth rate Q1, FY2026:23.73%
Forecast
Actual
Including amortisation and stock based compensations
Dr Reddys Laboratories Ltd EPS growth forecast
EPS estimate Q1, FY2026:7.51%
Forecast
Actual
Source: S&P Global Market Intelligence
Dr Reddys Laboratories Ltd Performance
Day's Low
Day's High
₹1,330.3Day's Price Range₹1,36752 Week's Low
52 Week's High
₹1,094.2452-Week Price Range₹1,421.49
| Returns % | |
| 1 Month Return | + 11.11 % |
| 3 Month Return | + 0.96 % |
| 1 Year Return | + 19.28 % |
| Market Stats | |
| Previous Close | ₹1,343.65 |
| Open | ₹1,362.00 |
| Volume | 37.40L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹1,12,115.62Cr |
Dr Reddys Laboratories Ltd Key Statistics
| P/E Ratio | 20.67 |
| PEG Ratio | 7.24 |
| Market Cap | ₹1,12,115.62 Cr |
| P/B Ratio | 4.22 |
| EPS | 66.882 |
| Dividend Yield | 0.65 |
| Sector | Pharmaceuticals |
| ROE | 19.42 |
Dr Reddys Laboratories Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹1,12,115.62 Cr | 26.2% | 0.52 | ₹5,577 Cr | ₹28,011 Cr | |
| HOLD | ₹1,55,212.84 Cr | 44.67% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,16,318.47 Cr | 53.62% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| HOLD | ₹40,334.16 Cr | 3.52% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| HOLD | ₹29,198.95 Cr | -0.52% | 0.50 | ₹772 Cr | ₹5,664 Cr |
Dr Reddys Laboratories Ltd Mutual Fund Holdings
About Dr Reddys Laboratories Ltd
Dr Reddy's Laboratories Ltd has a diverse portfolio of products and services, including prescription drugs, generic drugs, over-the-counter drugs, active pharmaceutical ingredients, biotechnology products, and nutraceuticals. Its most popular products include antibiotics, anti-infectives, anti-diabetics, anti-cancer, cardiovascular, gastrointestinal, and dermatology products. Some of its popular brands include Omez, Ciprocin, and Revital. It also has a strong presence in the generics market with its brands such as Reditux and Reditux-D.
Share Price: ₹1341.35 per share as on 23 Dec, 2024 04:01 PM
Market Capitalisation: ₹1,12,115.62Cr as of today
Revenue: ₹8,016.10Cr as on September 2024 (Q3 24)
Net Profit: ₹1,341.90Cr as on September 2024 (Q3 24)
Listing date: 03 Nov, 1994
Chairperson Name: K Satish Reddy
| Organisation | Dr Reddys Laboratories Ltd |
| Headquarters | Hyderabad |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Dr Reddys Laboratories Ltd
Dr Reddy's Laboratories Faces Mixed Outlook - 23 Dec, 2024
Dr Reddy's Laboratories has gained 9% over three sessions, driven by increased capex and growth in biosimilars. However, concerns over Revlimid's future earnings due to patent expiry and a high base from the previous year may hinder growth.Dr Reddy's Shares Surge on Upgrades and Growth Prospects - 20 Dec, 2024
Dr Reddy's Laboratories has seen significant share price increases due to Nomura's upgrade and strategic investments in manufacturing and biosimilars, marking a positive outlook for future growth.Nomura Upgrades Dr Reddy's to Buy Rating - 19 Dec, 2024
Nomura upgraded Dr Reddy's Laboratories to a Buy rating with a target price of Rs 1,500, citing growth potential despite recent profit declines. The stock gained over 4% following the upgrade, driven by expectations of market growth and low-competition launches in the US.Dr. Reddy's Launches Toripalimab in India - 17 Dec, 2024
Dr. Reddy's announced the launch of Toripalimab, an immune oncology drug for head and neck cancer, making India the third country to access it. The company has shown strong revenue growth and improved financial metrics over the past five years.Dr. Reddy's Launches Innovative Cancer Therapy in India - 12 Dec, 2024
Dr. Reddy's Laboratories has launched Zytorvi (toripalimab), a next-generation PD-1 inhibitor for recurrent nasopharyngeal carcinoma, marking a significant advancement in oncology treatment in India. This strategic partnership with Shanghai Junshi Biosciences allows exclusive rights to develop and market the drug in 21 countries, addressing unmet medical needs.Analysts Remain Optimistic on Dr Reddys Despite Profit Booking - 10 Dec, 2024
Despite recent profit-booking that has pulled Dr Reddys' stock from record highs, analysts maintain confidence in the company. Upgrades from sell to hold reflect cautious optimism, driven by anticipated revenue from Revlimid and potential drug launches. Enhanced R&D spending aims to strengthen its portfolio, although tangible results are awaited.Dr. Reddy's Subsidiary Fined by Kazakhstan Authorities - 06 Dec, 2024
Dr. Reddy's Laboratories announced that its subsidiary in Kazakhstan has been fined Rs 28.7 lakh due to a local tax dispute regarding expense claims for 2021.Dr Reddy's Unit Fined ₹28.7 Lakh in Kazakhstan - 05 Dec, 2024
Dr Reddys Laboratories announced that its subsidiary in Kazakhstan has been fined ₹28.7 lakh for disallowed expense claims. The company stated that this penalty will not materially impact its financials or operations.Dr Reddy's Focuses on Innovation and Market Growth - 04 Dec, 2024
Dr Reddy's Laboratories aims to enhance its domestic market position through innovation and new product launches, while also expanding its consumer health segment.Dr. Reddy’s Launches First NPC Immuno-Oncology Drug - 30 Nov, 2024
Dr. Reddy’s Laboratories has launched Toripalimab in India, the first immuno-oncology drug for nasopharyngeal carcinoma. This positions India as the third country to access this treatment, which shows a 48% reduction in disease progression risk when combined with standard chemotherapy.Dr Reddys Launches Cancer Drug, Stock Rises - 29 Nov, 2024
Dr Reddys Laboratories launched Toripalimab, an immunooncology drug for nasopharyngeal carcinoma, marking a significant milestone. The stock rose 2.1% following the announcement.Dr. Reddy's Launches First Immuno-Oncology Drug in India - 28 Nov, 2024
On November 28, Dr. Reddy's Laboratories launched Toripalimab, India's first immuno-oncology drug for nasopharyngeal carcinoma, after securing exclusive rights through a licensing agreement. This launch addresses a significant unmet medical need and positions India as the third country to access this treatment.Dr. Reddy's Faces Competition from Biocon - 26 Nov, 2024
Dr. Reddy's Laboratories competes with Biocon in the global pharmaceutical market, particularly in generics and biosimilars. While Dr. Reddy's has a strong presence in the US, Biocon's lower valuation and aggressive expansion into emerging markets make it a formidable competitor.Dr Reddys Laboratories Issues Product Recall in US - 25 Nov, 2024
Dr Reddys Laboratories is recalling 3,416 bottles of IBU (ibuprofen) 600 mg tablets in the US due to manufacturing issues, initiated on October 29. The recall is classified as Class III, indicating low risk of adverse health consequences.
Insights on Dr Reddys Laboratories Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTMF Holding Up
Mutual Funds have increased holdings from 10.05% to 10.86% in Sep 2024 quarter
- POSITIVE IMPACT
Price Rise
In the last 7 days, DRREDDY stock has moved up by 5.8%
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 3 quarters, 7.31K Cr → 8.35K Cr (in ₹), with an average increase of 6.4% per quarter
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 10.19% to 9.97% in Sep 2024 quarter
- NEGATIVE IMPACT
Promoter Holding Down
Promoters have decreased holdings from 26.65% to 26.64% in Sep 2024 quarter
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, 1.39K Cr → 1.25K Cr (in ₹), with an average decrease of 9.8% per quarter
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 27.68% to 27.53% in Sep 2024 quarter
News
Demand Concerns in Consumer Goods: Outlook for Q3
We continue to maintain our positive stance on the sector with demand continuing to trend better and increasing ASP with enhanced sales of the premium products.18 Dec, 2024 02:17 PMTop stocks for 2025: Axis Bank, Maruti Suzuki, KPIT Tech, Zee Entertainment, SAMIL among top 12 picks for JM Financial Services - Market News
In the short term, ex-Lloyd, consumer demand and growth momentum are expected to pick up driven by festive demand, pick-up in the real estate and capex cycle. Consumer sentiment has also started improving for the kitchen and domestic appliances portfolio. Over the medium/long term (ex-Lloyd), the brokerage expects volume to grow on the back of a pickup in construction activity, demand improvement from tier 2/3 cities, and market share gains. The brokerage believes (ex-Lloyd) revenue CAGR of 15% over FY24-FY27.16 Dec, 2024 10:22 AMDr Reddys Laboratories Ltd Financials
Index Inclusions
Dr Reddys Laboratories Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 26.64% | ||
| Foreign Institutions | 27.53% | ||
| Mutual Funds | 10.86% | 8.06 | |
| Retail Investors | 9.97% | ||
| Others | 24.99% |
Dr Reddys Laboratories Ltd Key Indicators
Dr Reddys Laboratories Ltd Valuation
Dr Reddys Laboratories Ltd in the last 5 years
Lowest (3.37x)
October 27, 2019
Today (20.67x)
December 19, 2024
Industry (56.23x)
December 19, 2024
Highest (53.88x)
December 18, 2020
Dr Reddys Laboratories Ltd Earnings and Dividends
Dr Reddys Laboratories Ltd Earnings Results
Dr Reddys Laboratories Ltd’s net profit fell -15.28% since last year same period to ₹1,255.70Cr in the Q2 2024-2025. On a quarterly growth basis, Dr Reddys Laboratories Ltd has generated -9.82% fall in its net profits since last 3-months.
Read More about Earnings ResultsDr Reddys Laboratories Ltd Dividends May,2024
In the quarter ending March 2024, Dr Reddys Laboratories Ltd has declared dividend of ₹40 - translating a dividend yield of 5.96%.
Read More about Dividends
Dr Reddys Laboratories Ltd Technicals Summary
Bearish
Neutral
Bullish
Dr Reddys Laboratories Ltd is currently in a Bullish trading position according to technical analysis indicators.
FAQs on Dr Reddys Laboratories Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Dr Reddys Laboratories Ltd shares.
Dr Reddys Laboratories Ltd (DRREDDY) share price today is ₹1341.35
Dr Reddys Laboratories Ltd is listed on NSE
Dr Reddys Laboratories Ltd is listed on BSE
- Today’s highest price of Dr Reddys Laboratories Ltd is ₹1367.
- Today’s lowest price of Dr Reddys Laboratories Ltd is ₹1330.3.
PE Ratio of Dr Reddys Laboratories Ltd is 20.67
PE ratio = Dr Reddys Laboratories Ltd Market price per share / Dr Reddys Laboratories Ltd Earnings per share
Today’s traded volume of Dr Reddys Laboratories Ltd(DRREDDY) is 37.40L.
Today’s market capitalisation of Dr Reddys Laboratories Ltd(DRREDDY) is ₹112115.62Cr.
| Dr Reddys Laboratories Ltd(DRREDDY | Price |
|---|---|
52 Week High | ₹1421.49 |
52 Week Low | ₹1094.24 |
Dr Reddys Laboratories Ltd(DRREDDY) share price is ₹1341.35. It is down -5.64% from its 52 Week High price of ₹1421.49
Dr Reddys Laboratories Ltd(DRREDDY) share price is ₹1341.35. It is up 22.58% from its 52 Week Low price of ₹1094.24
| Dr Reddys Laboratories Ltd(DRREDDY | Returns |
|---|---|
1 Day Returns | -2.3% |
1 Month Returns | 11.11% |
3 Month Returns | 0.96% |
1 Year Returns | 19.28% |